Dr Miguel Forte has joined Belgium biotechnology company Bone Therapeutics as its new chief medical officer.
Forte arrives at Bone Therapeutics with over 20 years of industry experience, most recently as chief operating and medical officer at TxCell and before that as chair of the commercialisation committee at the International Society of Cellular Therapy (ISCT).
His career to date has also seen him hold positions such as vice president, global medical affairs at UCB, as well as senior positions at the European Medicines agency, Bristol-Myers Squibb and Abbott.
Forte said: “The company has an advanced clinical pipeline with promising products in clinical development and I am impressed with its progress to date.
“I look forward to working with the Bone Therapeutics team to realise the potential of its ground breaking products for the benefits of the patients.”
In his new role Forte will oversee the company’s clinical development strategy and the advancement of its products to the market.
Thomas Lienard, chief executive officer at Bone Therapeutics, said: “His vast expertise in cell therapy will be a strong asset to our company and will further drive the progress of Bone Therapeutics’ innovative pipeline.
“In addition to his specific experience with cell therapy products, Dr Forte has extensive experience in interacting with regulatory bodies and establishing strong relationships with investigators and key opinion leaders.”